ARTG 474566Creatine kinase IVDs
ARTG ID: 474566 · Abacus dx Pty Ltd · Response Biomedical Corporation · Class IIb · Started December 23, 2024
Good Name: Abacus dx Pty Ltd - Creatine kinase IVDs
- Risk Class
- Class IIb
- Product Type
- IVD
- ARTG Category
- IVD
- ARTG ID
- 474566
- Start Date
- December 23, 2024
- Effective Date
- December 23, 2024
- Country
- Canada
- Address
- 1781 75th Avenue West, Vancouver, British Col, V6P 6P2
The RAMP CK-MB Assay is a quantitative immunochromatographic test indicated for use as an in vitro diagnostic product used to measure CK-MB levels in EDTA whole blood. Measurement of CK-MB aids in the rapid diagnosis of acute myocardial infarction (AMI). The RAMP CK-MB Assay is not intended to monitor reperfusion patients. The RAMP CK-MB Assay is intended to be used only to prioritize patient management for those suspected of AMI.
Access comprehensive regulatory information for Creatine kinase IVDs in the Australia medical device market through Pure Global AI's free TGA ARTG database. This Class IIb is registered under ARTG number 474566 and sponsored by Abacus dx Pty Ltd, manufactured by Response Biomedical Corporation in Canada. The device registration started on December 23, 2024.
This page provides complete registration details including sponsor information, manufacturer details, and regulatory compliance data from the official Australia TGA ARTG medical device database. Pure Global AI offers free access to Australia's complete medical device registry with 131,000+ devices, helping global MedTech companies navigate TGA regulations efficiently.